Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?

Abstract

Purpose To evaluate the clinical outcome of a cohort of localized prostate cancer patients treate with 125-I permanent brachytherapy at the São José Hospital – CHLC, Lisbon.Materials and Methods A retrospective analysis was carried out on 429 patients with low and intermediate-risk of prostate adenocarcinoma, according to the recommendations of the EORTC, who underwent 125I brachytherapies in intraoperative dosimetry “real-time” system between September 2003 and September 2013.Results The mean follow-up was 71.98 months. Biochemical relapse of disease by rising PSA (Phoenix criterion) was observed in 18 patients (4.2%). Through the application of Kaplan-Meier survival curves in this sample, the rate of survival at 6 years without biochemical relapse was higher than 95%. By Iog rank test comparing biochemical relapse with initial PSA (15-10 and <10) and Gleason values (7 and <7), there was no statistical difference (P=0.830) of the initial PSA in the probability of developing biochemical relapse. In relation to Gleason score, it was noted a statistical difference (P<0.05), demonstrating that patients with Gleason 7 are more likely to develop biochemical relapse.Conclusions Brachytherapy as monotherapy is at present an effective choice in the treatment of localized prostate adenocarcinoma. Biochemical relapses are minimal. The initial PSA showed no statistically difference in the rate of relapses, unlike the value Gleason, where it was demonstrated that patients with Gleason 7 have a higher probability of biochemical relapse. Cases with PSA bounce should be controlled before starting a salvage treatment.

Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study

“…In addition, a Portuguese single-centre retrospective study ( 31 ) was identified that reported 6-year real-world outcomes in non-high-risk LPC [defined according to European Organisation for Research and Treatment of Cancer ( 32 )] between 2003 and 2013; however, in this previous study, the patients were only treated with brachytherapy, and therefore it cannot be used for comparing outcomes or treatment patterns with the present study.…”

Prognostic Factors for Overall Survival of Patients with Prostate Cancer in Kyadondo County, Uganda

“…Parra et al in Spain reported that GS 8 was the main score with the ability to predict independently the OS of the patients with a statistical significance (푝 = 0.006) [30]. Galego et al in Portugal reported a correlation between 5-year OS and GS (푝 < 0.05) [31]. In their study they also found that GS 7 was an independent predictor of the biochemical relapse of the disease unlike PSA.…”

“…In their study they also found that GS 7 was an independent predictor of the biochemical relapse of the disease unlike PSA. Early detection of PCa is usually linked with low stage at diagnosis as well as low tumour grade [31,32]. For countries where screening of PCa is massive and sustainable, it has been found that most of the patients are diagnosed at early stage and for that matter they have low tumour grade which is usually determined by GS [33].…”

Analysis of Cells Proliferation and MicroRNAs Expression Profile in Human Chondrosarcoma SW1353 Cells Exposed to Iodine-125 Seeds Irradiation

“…Nowadays, interstitial implantation of 125 I seeds has been used to treat prostate cancer, and some other forms of recurrent or inoperable malignancies, such as non-small cell lung cancer, pancreatic cancer, and intracranial gliomas. [4][5][6][7][8] Previously, Ren et al 3 reported the use of 125 I seeds placed into the resected tumor bed of a patient with recurrent lumbar vertebral chondrosarcoma who underwent marginal resection. Although the pathology specimen was showed conventional low-grade chondrosarcoma, the treatment was effective, with no signs of recurrence at the 2-year follow-up.…”